Drug
MAAT013 clinical trials
Also written MaaT013.
- studies test it
- 3
- open now
- 0
- in phase 3
- 1
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
MaaT Pharma (2) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Ipilimumab (1) · Nivolumab (1) · MoviPrep (1) · Normacol (1)
Studies
Open first, then newest update. How each study uses MAAT013 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT04988841Written as MaaT013
- MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD PatientsActive, not recruitingPhase 3MaaT PharmaNCT04769895Written as MaaT013
- Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSferCompletedPhase 2MaaT PharmaNCT03359980Written as fecal microbiota transfer